AU2016367112B2 - Combination for the effective treatment of metastatic cancer in patients - Google Patents

Combination for the effective treatment of metastatic cancer in patients Download PDF

Info

Publication number
AU2016367112B2
AU2016367112B2 AU2016367112A AU2016367112A AU2016367112B2 AU 2016367112 B2 AU2016367112 B2 AU 2016367112B2 AU 2016367112 A AU2016367112 A AU 2016367112A AU 2016367112 A AU2016367112 A AU 2016367112A AU 2016367112 B2 AU2016367112 B2 AU 2016367112B2
Authority
AU
Australia
Prior art keywords
cancer
approximately
ascorbic acid
dose
hydroxocobalamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016367112A
Other languages
English (en)
Other versions
AU2016367112A1 (en
Inventor
Arnold Glazier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Oncology Inc
Original Assignee
General Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Oncology Inc filed Critical General Oncology Inc
Publication of AU2016367112A1 publication Critical patent/AU2016367112A1/en
Priority to AU2022200131A priority Critical patent/AU2022200131A1/en
Application granted granted Critical
Publication of AU2016367112B2 publication Critical patent/AU2016367112B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016367112A 2015-12-07 2016-12-06 Combination for the effective treatment of metastatic cancer in patients Active AU2016367112B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200131A AU2022200131A1 (en) 2015-12-07 2022-01-11 Combination for the effective treatment of metastatic cancer in patients

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263880P 2015-12-07 2015-12-07
US62/263,880 2015-12-07
PCT/US2016/065079 WO2017100162A1 (en) 2015-12-07 2016-12-06 Combination for the effective treatment of metastatic cancer in patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200131A Division AU2022200131A1 (en) 2015-12-07 2022-01-11 Combination for the effective treatment of metastatic cancer in patients

Publications (2)

Publication Number Publication Date
AU2016367112A1 AU2016367112A1 (en) 2018-07-12
AU2016367112B2 true AU2016367112B2 (en) 2022-01-13

Family

ID=57708742

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016367112A Active AU2016367112B2 (en) 2015-12-07 2016-12-06 Combination for the effective treatment of metastatic cancer in patients
AU2022200131A Abandoned AU2022200131A1 (en) 2015-12-07 2022-01-11 Combination for the effective treatment of metastatic cancer in patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200131A Abandoned AU2022200131A1 (en) 2015-12-07 2022-01-11 Combination for the effective treatment of metastatic cancer in patients

Country Status (14)

Country Link
US (3) US11154520B2 (enExample)
EP (1) EP3386546B1 (enExample)
JP (3) JP6831853B2 (enExample)
KR (1) KR20180086257A (enExample)
AU (2) AU2016367112B2 (enExample)
CA (1) CA3044959C (enExample)
DK (1) DK3386546T3 (enExample)
ES (1) ES2994931T3 (enExample)
FI (1) FI3386546T3 (enExample)
HU (1) HUE069668T2 (enExample)
IL (2) IL290251B2 (enExample)
PL (1) PL3386546T3 (enExample)
PT (1) PT3386546T (enExample)
WO (1) WO2017100162A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3721878A1 (en) 2012-10-22 2020-10-14 Arnold Glazier Methods for the effective treatment of metastatic cancer
US11298338B2 (en) * 2016-06-06 2022-04-12 University Of Iowa Research Foundation Compositions and methods for cancer therapy
EP3840744B1 (en) 2018-08-21 2025-06-04 Board of Regents, The University of Texas System Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress
CN114904011B (zh) * 2021-07-06 2023-10-13 中国科学院上海硅酸盐研究所 非铁基谷胱甘肽消耗协同活性氧物种增强复合材料及其制备方法和应用
EP4376822A4 (en) * 2021-07-29 2025-09-17 Lantern Pharma Inc TREATMENT OF CANCER WITH COMBINATIONS OF PARP INHIBITORS AND ACYLFULVENS
CN116407557A (zh) * 2023-05-29 2023-07-11 四川大学华西医院 一种防治出血性脑卒中的药物组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150265641A1 (en) * 2012-10-22 2015-09-24 Arnold Glazier Methods for the Effective Treatment of Metastatic Cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1305873C (en) * 1987-05-26 1992-08-04 Howel Gwynne Giles Method and means for detecting alcohol levels in humans
US5639787A (en) 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
CA2371728C (en) 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
EP1313508B1 (en) * 2000-06-30 2007-04-18 Eli Lilly And Company Combination containing an antifolate and methylmalonic acid lowering agent
ES2303588T3 (es) 2002-03-22 2008-08-16 Ludwig Maximilians Universitat Ensayo de citocapacidad.
ES2421516T3 (es) 2002-11-06 2013-09-03 Dana Farber Cancer Inst Inc Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341
US20090123447A1 (en) * 2007-11-14 2009-05-14 The Regents Of The University Of California Compositions and methods to inhibit rna viral reproduction
EP2456306A4 (en) * 2009-07-20 2012-12-26 Summa Health System VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING OESTOLYSIS OR EXTENDING A PROTEST IMPLANT

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150265641A1 (en) * 2012-10-22 2015-09-24 Arnold Glazier Methods for the Effective Treatment of Metastatic Cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Akatov V. S. et al., "Oxidative stress in HEp-2 human laryngel carcinoma cells induced by combination of vitamins B12 and C", BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, (2003), vol. 136, no. 3, pages 279 - 282 *
Pierson H. F. et al., "Depletion of extracellular cysteine with hydroxocobalamin and ascorbate in experimental murine cance", CANCER RESEARCH, (1985), vol. 45, pages 4727 - 4731 *
Poydock M. E. et al., "Effect Of Combined Ascorbic Acid And B-12 On Survival Of Mice With Implanted Ehrlich Carcinoma And L1210 Leukemia", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, (1991), vol. 54, no. 6, pages 1261S - 1265S *
Poydock M. E. et al., "Growth-inhibiting effect of hydroxocobalamin and L-ascorbic acid on two solid tumors in mice", IRCS MEDICAL SCIENCE, (1984), vol. 12, page 813 *
Poydock M. E. et al., "Influence of vitamins C and B12 on the survival rate of mice bearing ascites tumor", EXPERIMENTAL CELL BIOLOGY, (1982), vol. 50, no. 2, pages 88 - 91 *

Also Published As

Publication number Publication date
EP3386546A1 (en) 2018-10-17
US20220096405A1 (en) 2022-03-31
AU2022200131A1 (en) 2022-02-10
JP6831853B2 (ja) 2021-02-17
PL3386546T3 (pl) 2025-01-27
IL259512B2 (en) 2024-03-01
JP2019501962A (ja) 2019-01-24
FI3386546T3 (fi) 2024-12-05
DK3386546T3 (en) 2024-11-25
IL259512B1 (en) 2023-11-01
US11154520B2 (en) 2021-10-26
PT3386546T (pt) 2024-12-09
JP7144554B2 (ja) 2022-09-29
CA3044959A1 (en) 2017-06-15
IL259512A (en) 2018-07-31
ES2994931T3 (en) 2025-02-04
IL290251B2 (en) 2024-07-01
CA3044959C (en) 2024-01-09
EP3386546B1 (en) 2024-09-04
IL290251A (en) 2022-04-01
JP2021073262A (ja) 2021-05-13
US20240216308A1 (en) 2024-07-04
AU2016367112A1 (en) 2018-07-12
HUE069668T2 (hu) 2025-04-28
KR20180086257A (ko) 2018-07-30
IL290251B1 (en) 2024-03-01
JP2022171816A (ja) 2022-11-11
US20180338935A1 (en) 2018-11-29
WO2017100162A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
JP7144554B2 (ja) 患者における転移性癌の有効な治療のための組合せ
Tao et al. Targeting hypoxic tumor microenvironment in pancreatic cancer
Heffner et al. Pulmonary strategies of antioxidant defense 1
Coleman et al. 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer
Kaweme et al. The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications
Wenzel et al. ALDH-2 deficiency increases cardiovascular oxidative stress---Evidence for indirect antioxidative properties
US20240024344A1 (en) Methods For The Effective Treatment Of Metastatic Cancer
CA3152258A1 (en) Compositions and methods for treating metastatic gastrointestinal cancer
Li Vitamin C, a multi-tasking molecule, finds a molecular target in killing cancer cells
Shi et al. Anti‐Tumor Strategies Targeting Nutritional Deprivation: Challenges and Opportunities
Ahmad Ganai et al. Plant derived inhibitor Sulforaphane in combinatorial therapy against therapeutically challenging Pancreatic Cancer
HK1261631A1 (en) Combination for the effective treatment of metastatic cancer in patients
PT1694338E (pt) Utilização de miméticos da superóxido dismutase e de glutationa redutase sob a forma de fármacos anticancerosos
HK40039081A (en) Methods for the effective treatment of metastatic cancer
JP2007527428A (ja) トポイソメラーゼｉｉ阻害剤、ビス−ジオキシピペラジン及び放射線を用いた癌治療
Boivin et al. Transient Alteration of Cellular Redox Buffering before Irradiation Triggers Apoptosis
Rawal Manganoporphyrins as adjuvants to enhance pharmacological ascorbate in pancreatic cancer therapy
Huxham The tumour microenvironment: mapping the microregional effects of drugs
Moon In Vitro and In Vivo Studies of Chemotherapeutic Doxorubicin Analogs
Millard Discovery of novel small molecules targeting cancer cell metabolism
Karpel-Massler et al. Running title: Targeting IDH1 in Glioma Correspondence to
WO2011056663A1 (en) Method of treating cancer using combination of a bifunctional alkylating agent and dna repair inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)